The Prognostic and Molecular Landscape of Autophagy-Related Long Noncoding RNA in Colorectal Cancer

Figure 9

Antineoplastic therapy susceptibility and MSI analysis. (a–c) The boxplots showing the statistical differences of the expression of tumor immune check points (PDCD1, CTLA4, and HAVCR2) in the high- and low-risk groups. (d) The violin plot illustrating the TIDE score of the low-risk group was higher than that in the high-risk group with statistical significance (). (e–i) The boxplots showing the statistical differences in the IC50 of gefitinib, PLX4720, AZD.2281, cisplatin, and JNK.inhibitor.VIII in the high- and low-risk groups. (j) The bar plot depicting the distribution differences of CRC patients with different MSI statuses in the high- and low-risk groups. (k) The boxplots showing the statistical differences of the expression of characteristic genes (PMS2, MSH6, MSH2, and MLH1) of the MMR system in the high- and low-risk groups. (l) The correlation heat map illustrating the coexpression correlation among the four characteristic genes (PMS2, MSH6, MSH2, and MLH1) and six ARlncRNAs (ALMS1-IT1, FGD5-AS1, FLG-AS1, MIR210HG, MIR31HG, and PINK1-AS) of the prognostic signature.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)